Skip Navigation


Hum. Reprod. Advance Access originally published online on February 24, 2009
Human Reproduction 2009 24(6):1322-1329; doi:10.1093/humrep/den481
This Article
Right arrow Full Text
Right arrow Full Text (PDF )
Right arrow All Versions of this Article:
24/6/1322    most recent
den481v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Carmely, A.
Right arrow Articles by Sredni, B.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carmely, A.
Right arrow Articles by Sredni, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Protective effect of the immunomodulator AS101 against cyclophosphamide-induced testicular damage in mice

A. Carmely1, D. Meirow2,4, A. Peretz1, M. Albeck3, B. Bartoov1,{dagger} and B. Sredni1,{dagger}

1 The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel 2 IVF Unit, Division of Obstetrics and Gynecology, Sheba Medical Center, Tel-Hashomer, Israel 3 Department of Chemistry, Faculty of Exact Sciences, Bar-Ilan University, Ramat-Gan, Israel

4 Correspondence address. Tel: +972 3 5302882; Fax: +972 3 5341589; E-mail: meirow{at}post.tau.ac.il

BACKGROUND: Cyclophosphamide (Cy), a widely used anticancer drug, is associated with significant testicular damage and sterility. Co-administration of the immunomodulating compound AS101 during chemotherapy treatments was previously shown to protect organs against cytotoxic damage, without attenuating the drug’s anticancer effect. In this animal study, we investigated the effect of AS101 on testicular damage, sperm DNA damage and infertility induced by Cy. Akt and glycogen synthase kinase-3β (GSK-3β) phosphorylation were investigated as a possible chemoprotective mechanism.

METHODS: Mature male mice, 10 in each group, were injected intraperitoneally with 200 mg/kg Cy once a week for 5 weeks, with or without concurrent treatment with 10 µg per mouse AS101 three times per week. Damage to testicular tubules and sperm production was determined, sperm chromatin damage was analyzed and fertility was gauged. Akt and GSK-3β phosphorylation were evaluated.

RESULTS: Co-treatment with AS101 during the course of Cy administration significantly reduced the percentage of damaged seminiferous tubules (76.0 ± 10.8% versus 40.3 ± 2.6%), and reduced sperm DNA fragmentation (%DFI) from 44.7 ± 1.0% to 25 ± 6.5%. Co-treatment with AS101 also partially protected against the decrease in numbers of impregnated females and litter size. AS101 increased Akt and GSK-3β phosphorylation.

CONCLUSIONS: Our results indicate that AS101 can significantly protect against Cy-induced testicular damage and sperm DNA damage, probably by acting through Akt/GSK-3β phosphorylation.

Key words: AS101/testicular damage/sperm DNA damage/chemotherapy/fertility preservation

{dagger} Both authors contributed equally to the study.

Submitted on August 17, 2008; resubmitted on October 26, 2008; accepted on November 15, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.